SAB Biotherapeutics (SABS) Interest Coverage Ratio (2021 - 2026)
SAB Biotherapeutics (SABS) reported Interest Coverage Ratio of 318.71 for Q1 2026, down 105.82% on a YoY basis from 5474.2 in Q1 2025, and down 28.26% quarter-over-quarter from 248.5 in Q4 2025.
SAB Biotherapeutics (SABS) Interest Coverage Ratio (2021 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Interest Coverage Ratio for 6 years, with the latest figure at 318.71 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio fell 105.82% year-over-year to 318.71; the trailing twelve-month figure through Mar 2026 stood at 248.79 (down 83.3% YoY), and the FY2025 full-year result was 203.41, down 50.93% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 318.71, down from 248.5 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 195.3 in Q4 2022, with the low at 318.71 in Q1 2026.
- Historically, Interest Coverage Ratio has averaged 135.06 across 5 years, with a median of 141.22 in 2024.
- The largest YoY upside for Interest Coverage Ratio was 276.24% in 2022 against a maximum downside of 960.35% in 2022.
- SAB Biotherapeutics' Interest Coverage Ratio stood at 195.3 in 2022, then tumbled by 224.09% to 242.35 in 2023, then soared by 41.73% to 141.22 in 2024, then tumbled by 75.97% to 248.5 in 2025, then dropped by 28.26% to 318.71 in 2026.
- The last three Interest Coverage Ratio figures came in at 318.71 (Q1 2026), 248.5 (Q4 2025), and 292.87 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | -318.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -318.71 |
| Dec 31, 2025 | -248.50 |
| Sep 30, 2025 | -292.87 |
| Jun 30, 2025 | -151.25 |
| Mar 31, 2025 | -154.85 |
| Dec 31, 2024 | -141.22 |
| Sep 30, 2024 | -144.92 |
| Jun 30, 2024 | -109.56 |
| Mar 31, 2024 | -149.15 |
| Dec 31, 2023 | -242.35 |
| Sep 30, 2023 | -76.37 |
| Jun 30, 2023 | -85.99 |
| Mar 31, 2023 | -80.12 |
| Dec 31, 2022 | 195.30 |
| Sep 30, 2022 | -110.54 |
| Jun 30, 2022 | -91.85 |
| Mar 31, 2022 | -93.13 |
| Dec 31, 2021 | -110.81 |
| Sep 30, 2021 | -50.80 |
| Jun 30, 2021 | -38.59 |